AU2285800A - New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases - Google Patents

New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases

Info

Publication number
AU2285800A
AU2285800A AU22858/00A AU2285800A AU2285800A AU 2285800 A AU2285800 A AU 2285800A AU 22858/00 A AU22858/00 A AU 22858/00A AU 2285800 A AU2285800 A AU 2285800A AU 2285800 A AU2285800 A AU 2285800A
Authority
AU
Australia
Prior art keywords
group
alpha
membered ring
bond
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22858/00A
Inventor
Arwed Cleve
Jens Hoffmann
Christoph Huwe
Karsten Parczyk
Gerhard Sauer
Martin Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2285800A publication Critical patent/AU2285800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/0037—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to new 7 alpha , 17 alpha , 17 beta -substituted testosterone derivatives of general formula (I) and their use as pure antiandrogens for the long-term therapy of androgen-dependent diseases, notably for the long-term antiandrogen therapy of prostate carcinoma. In the general formula (I) A is an unbranched C6-C13-alkylene group; B is an oxygen atom, -S(O)p- group, in which p is 0, 1 or 2, an iminocarbonyl group -C(O)N(Y)-, an imino group -N(Y)-, a carbonylimino group -N(Y)C(O)-, a sulfonylimino group -NN(Y)S(O)2-, where Y is a hydrogen atom or a C1-C8-alkyl group, a sulfonyloxy group -OS(O)2-, a dimethylsilyloxy group -O--Si(CH3)2- or a carbonylsulfanyl group -SC(O)- or a bond between A and C or, together with C, a bond between A and D; C is a bond between B and D or, together with B, a bond between A and D or an unbranched C1-C6-alkylene group, a phenylene group, a substituted phenylene group, a five-membered ring or six-membered ring heteroarylene group, a substituted five-membered ring or six-membered ring heteroarylene group or a five-membered ring or six-membered ring heteroarylene group fused with a phenyl ring; and D is a hydrogen atom, a C1-C4-alkyl group, a vinyl group, a C1-C4-alkoxy group, a C1-C4-alkoxycarbonyl group, a bis(C1-C4-alkoxycarbonyl)methyl group, an acetyl(C1-C4-alkoxycarbonyl)methyl group, a cyan group, a carboxy group, an azide group, a hydroxy group, a halogen atom or a rest of the formula CnFmHo, in which n is 1, 2, 3 or 4, m > 1 and m+o = 2n+1.
AU22858/00A 1998-12-23 1999-12-23 New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases Abandoned AU2285800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19860719 1998-12-23
DE19860719A DE19860719A1 (en) 1998-12-23 1998-12-23 New testosterone derivatives and their use for long-term therapy of androgen-dependent diseases
PCT/EP1999/010355 WO2000039148A1 (en) 1998-12-23 1999-12-23 New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases

Publications (1)

Publication Number Publication Date
AU2285800A true AU2285800A (en) 2000-07-31

Family

ID=7893124

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22858/00A Abandoned AU2285800A (en) 1998-12-23 1999-12-23 New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases

Country Status (7)

Country Link
EP (1) EP1140972B1 (en)
JP (1) JP2002533471A (en)
AT (1) ATE233782T1 (en)
AU (1) AU2285800A (en)
DE (2) DE19860719A1 (en)
NO (1) NO20013168L (en)
WO (1) WO2000039148A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100396693C (en) * 2006-11-08 2008-06-25 浙江大学 Preparation method of 1,4-dipregnene-16-beta-methyl-17-alpha-21-bihydroxy object

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10049736A1 (en) * 2000-09-29 2002-04-18 Jenapharm Gmbh Alpha-fluoroalkyl steroids, processes for their preparation and pharmaceutical compositions containing them
MXPA03006156A (en) * 2001-01-09 2003-09-16 Schering Ag The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment.
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
ES2642767T3 (en) † 2013-05-30 2017-11-20 Agc Glass Europe Solar control glazing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341557A (en) * 1961-06-05 1967-09-12 Upjohn Co 7-methyltestosterones
JP2959839B2 (en) * 1989-07-07 1999-10-06 アンドルシェルシュ・インコーポレイテッド Androgen derivatives for use in inhibiting sex steroid activity
WO1993013122A1 (en) * 1991-12-22 1993-07-08 Schering Aktiengesellschaft 3-methylsulphonylhydrazono and 3-oxyimino steroids, a method of preparing them, pharmaceutical preparations containing them and their use in the preparation of drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100396693C (en) * 2006-11-08 2008-06-25 浙江大学 Preparation method of 1,4-dipregnene-16-beta-methyl-17-alpha-21-bihydroxy object

Also Published As

Publication number Publication date
NO20013168D0 (en) 2001-06-22
WO2000039148A1 (en) 2000-07-06
DE59904499D1 (en) 2003-04-10
EP1140972A1 (en) 2001-10-10
NO20013168L (en) 2001-06-22
DE19860719A1 (en) 2000-06-29
ATE233782T1 (en) 2003-03-15
JP2002533471A (en) 2002-10-08
EP1140972B1 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
IT1255191B (en) BISBENZOFURAN-2-ONI
ES2186017T3 (en) PROCEDURES FOR THE PREPARATION OF DELTA 4,5-STEROIDS 3-CETO-7ALFA-ALCOXICARBONIL-SUBSTITUTES AND INTERMEDIATE COMPOUNDS OF USEFULNESS.
PT1827427E (en) Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
DE602005021130D1 (en) USE OF 3-SUBSTITUTED THIOPHENES AS FRAGRANCES AND AROMAS
AU2285800A (en) New 7-alpha, 17-alpha-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases
HUP0303241A2 (en) Pyrazolyl pyrimidines, preparing and use thereof and the intermediates used in this process
ATE263771T1 (en) TOTAL SYNTHESIS OF ACYLFULVENE WITH ANTITUMOR EFFECT
MXPA05011829A (en) Polytrimethylene ether glycol with excellent quality from biochemically-derived 1,3-propanediol.
BR9814897A (en) S-oxide and s, s-phenyloxazolidinones tetrahydrothiopyrane
FR2751882B1 (en) HYPERBACTERICIDAL SURFACES
ATE280767T1 (en) ANTIDIABETIC THIAZOLIDINDIONES AND THEIR PRODUCTION
EP1288275A3 (en) Electrochromic solution containing a hydrazone compound and device manufactured with same
AU5789790A (en) Benzaldehyde derivatives
MX2007006758A (en) Benzdioxane piperazine derivatives with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites.
EP0236916A3 (en) N-aryltetrahydrophthalimide derivatives and their precursors
NO824253L (en) 2-AMINO-1- (1,3-DIOXOLAN-4-YL) -ETHANOLE COMPOUNDS, PREPARATION OF THESE AND USE OF THESE AS BASIC MATERIALS
ATE246703T1 (en) ORAL ACTIVE 7-ALPHA-ALKYL ANDROGENS
EP1375489A4 (en) Medicinal composition containing 1,3-thiazine derivative
ES456400A1 (en) Thienothiazine derivatives
FI932691A0 (en) New benzyl and benzhydryl alcohol
HUP0001397A2 (en) 3-amino-3-arylpropan-1-ol derivatives, production and use thereof
ES2177087T3 (en) DERIVATIVES OF VINYL ETERES.
TW200634009A (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
ATE381553T1 (en) THIOCARBONATES AS A PRECURSOR OF FLAVORS
DE60334549D1 (en) IMPROVED ROTATING SLEEVE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase